Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

@article{Cutter1999DevelopmentOA,
  title={Development of a multiple sclerosis functional composite as a clinical trial outcome measure.},
  author={G. Cutter and M. Baier and R. Rudick and D. Cookfair and J. Fischer and J. Petkau and K. Syndulko and B. Weinshenker and J. Antel and C. Confavreux and G. Ellison and F. Lublin and A. Miller and S. Rao and S. Reingold and A. Thompson and E. Willoughby},
  journal={Brain : a journal of neurology},
  year={1999},
  volume={122 ( Pt 5)},
  pages={
          871-82
        }
}
The primary clinical outcome measure for evaluating multiple sclerosis in clinical trials has been Kurtzke's expanded disability status scale (EDSS). New therapies appear to favourably impact the course of multiple sclerosis and render continued use of placebo control groups more difficult. Consequently, future trials are likely to compare active treatment groups which will most probably require increased sample sizes in order to detect therapeutic efficacy. Because more responsive outcome… Expand
1,027 Citations

Paper Mentions

Interventional Clinical Trial
STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3… Expand
ConditionsMultiple Sclerosis, Relapsing-Remitting
InterventionBiological, Other
Interventional Clinical Trial
STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3… Expand
ConditionsMultiple Sclerosis, Relapsing-Remitting
InterventionBiological, Other
Interventional Clinical Trial
STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3… Expand
ConditionsMultiple Sclerosis, Relapsing-Remitting
InterventionBiological, Other
Interventional Clinical Trial
Fampridine-SR is registered for the treatment of walking incapacity in MS patients. Two pivotal trials show that app. 40% of MS patients with walking incapacity can improve walking… Expand
ConditionsMultiple Sclerosis
InterventionDrug
Clinical Outcome Measures for Research in Multiple Sclerosis
  • L. Balcer
  • Medicine
  • Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • 2001
  • 58
Possible clinical outcome measures for clinical trials in patients with multiple sclerosis
  • 107
  • PDF
Outcome Measures in Clinical Trials for Multiple Sclerosis
  • 65
  • PDF
Functional clinical outcomes in multiple sclerosis: Current status and future prospects.
  • 19
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 58 REFERENCES
Recommendations from the national multiple sclerosis society clinical outcomes assessment task force
  • 347
Clinical outcomes assessment in multiple sclerosis
  • 166
Outcomes assessment in multiple sclerosis clinical trials: a critical analysis
  • 232
Meta-analysis of the placebo-treated groups in clinical trials of progressive MS
  • 63
A New Scale for Evaluating Disability in Multiple Sclerosis
  • 263
  • Highly Influential
...
1
2
3
4
5
...